Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Vitronectin in clotting factor IX concentrates
Autore:
Josic, D; Kannicht, C; Loster, K; Pock, K; Iberer, G; Buchacher, A;
Indirizzi:
Octapharma Pharmazeut Prod Ges mbH, A-1100 Vienna, Austria Octapharma Pharmazeut Prod Ges mbH Vienna Austria A-1100 Vienna, Austria Octapharma Pharmazeut, Biochem Lab, Berlin, Germany Octapharma PharmazeutBerlin Germany zeut, Biochem Lab, Berlin, Germany
Titolo Testata:
HAEMOPHILIA
fascicolo: 3, volume: 7, anno: 2001,
pagine: 250 - 257
SICI:
1351-8216(200105)7:3<250:VICFIC>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLASMINOGEN-ACTIVATOR INHIBITOR-1; THROMBIN-ANTITHROMBIN-III; HUMAN-PLASMA; PROTHROMBIN COMPLEX; HEMOPHILIA-B; CHROMATOGRAPHY; HEPARIN; PURITY; MECHANISM; PROTEINS;
Keywords:
binding; coagulation factor IX concentrates; heparin; multimeric forms; vitronectin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Josic, D Octapharma Pharmazeut Prod Ges mbH, Oberlaaer Str 235, A-1100 Vienna, Austria Octapharma Pharmazeut Prod Ges mbH Oberlaaer Str 235 Vienna Austria A-1100
Citazione:
D. Josic et al., "Vitronectin in clotting factor IX concentrates", HAEMOPHILIA, 7(3), 2001, pp. 250-257

Abstract

Highly purified, plasma-derived factor IX (FIX) concentrates are produced in large part by a combination of anion exchange and heparin affinity chromatography. However, the concentrates still contain some accompanying proteins. The main impurity has turned out to be the adhesive glycoprotein, vitronectin. It occurs in concentrates exclusively in its multimeric form, in contrast to the situation in plasma. The multimeric vitronectin can be removed either by nanofiltration with a crossflow system or by size-exclusion chromatography. When these FIX concentrates are used as therapeutic agents, the fact has to be taken into account that considerable amounts of multimericvitronectin are given to the patient. The physiological consequences of the dosage of this protein have not yet been investigated. Although no thrombogenicity has been reported in connection with the above-mentioned FIX concentrates, we recommend that the impurity should be removed from the preparation with the methods described here.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:19:43